|Day's Range||0.040 - 0.045|
|52 Week Range||0.030 - 0.290|
|PE Ratio (TTM)||-0.58|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FluoroPharma Medical, Inc. reports preliminary financial results for the quarter ended June 30, 2015.We analyze the earnings along side the following peers of FluoroPharma Medical, Inc. – Studsvik AB Unsponsored ADR and PharmAthene, Inc. (SUDKY-US and PIP-US) that have also reported for this period.HighlightsThe table below shows the preliminary results and recent trends for key (Read more...) The post FluoroPharma Medical, Inc. Earnings Q2, 2015 appeared first on CapitalCube.
We are maintaining our Buy recommendation. See below for free access to our updated report on FPMI. Authors of the article, titled A New F-18 Labeled PET Tracer For Fatty Acid Imaging, note that initial data from the study has shown CardioPET can better identify differences in fatty acid uptake as compared to the comparator, that is Tc-99m-SPECT, in the evaluation of CAD. Specifically, in a patient with CAD that underwent a stress test, CardioPET identified differences in fatty acid (FA) uptake in areas where Tc-99m-SPECT showed no abnormalities. As fatty acid uptake will decrease with acute or chronic myocardial ischemia, accurately identifying decreased uptake is important in diagnosing the full extent of coronary stenosis (i.e.
By Brian Marckx, CFA OTC:FPMI We have updated our report on FluoroPharma Medical (OTC:FPMI). See below for free access to our full report on the company. Development of FluoroPharma's CardioPET nuclear ...